The pharmaceutical industry is still growing rapidly under the epidemic

China's pharmaceutical industry revenue steady growth. However, affected by the epidemic this year, the profits of Industrial Enterprises above designated size decreased by 38.3% year-on-year from January to February, while the profits of pharmaceutical industry decreased by 10.9% year-on-year, significantly less than that of all industries above Designated Size (data from the National Bureau of Statistics).

Statistics of Hebei and Guangdong show that the pharmaceutical industry in Hebei and Guangdong grew rapidly from January to February. In the future, we hope that the pharmaceutical industry will maintain the momentum of sustainable development. Hebei increased by 12.5% year-on-year, Hebei news. It was learned from Hebei Provincial Department of industry and information technology that, driven by the rapid resumption of production, the growth rate of industrial added value above Designated Size in Hebei Province was 4.1 percentage points higher than the national average in January February. The added value of tobacco products, medicine, electronic equipment manufacturing, agricultural and sideline food processing and other industries rose against the trend, with a year-on-year growth of 25.2%, 12.5%, 9.8% and 3.7% respectively. Guangdong grew 8.5% in February, Nandu news Guangdong Provincial Bureau of Statistics recently announced the economic operation of Guangdong from January to February. In 1-2 months, novel coronavirus pneumonia had a short-term impact on Guangdong's economy. But at the same time, the pharmaceutical manufacturing industry maintained a good growth, with the pharmaceutical manufacturing industry growing 8.5% in February. From January to February, the added value of the manufacturing industry of biological pharmaceutical products increased by 7.0%, of which 30.8% in February; the added value of the manufacturing industry of health materials and medical supplies increased by 7.9%, of which 70.5% in February; the added value of the pharmaceutical auxiliary materials and packaging materials increased by 18.7%, of which 58.6% in February.

From January to February, the added value of medical equipment and equipment manufacturing industry increased by 1.7%, among which: the added value of medical diagnosis, monitoring and treatment equipment manufacturing increased by 18.1%; the added value of rehabilitation auxiliary equipment manufacturing increased by 7.6%. From January to February, there were 58 mask manufacturers in industries above Designated Size in the province, with a year-on-year growth of 180.8% in total, including 155.2% in medical masks. In 2019, the revenue of China's pharmaceutical industry grew steadily. In 2019, the operating revenue of Industrial Enterprises above Designated Size in the pharmaceutical manufacturing industry reached 2390.86 billion yuan, an increase of 7.4% year on year, 3.6 percentage points higher than the overall level of Industrial Enterprises above Designated Size in China over the same period. The operating cost was 1350.54 billion yuan, an increase of 5.7% year on year, 1.6 percentage points higher than the overall level of Industrial Enterprises above Designated Size in the same period. The total profit was 311.95 billion yuan, an increase of 5.9% year on year, 9.2 percentage points higher than the overall level of Industrial Enterprises above Designated Size in the same period.

The profit margin of pharmaceutical manufacturing business income is about 13.05%, 0.3 percentage points higher than the same period of last year, and 7.19 percentage points higher than the overall level of Industrial Enterprises above Designated Size in the same period. (data source: National Bureau of Statistics) in 2019, 86 application numbers of simplified new drug application (anda) were approved by the US FDA by Chinese pharmaceutical enterprises, including 13 temporary approvals and 3 first generic drugs. Fosun Pharmaceutical and Nantong Lianya are the two most approved enterprises, and TEDA pharmaceutical, Yongtai pharmaceutical, Jutai pharmaceutical, Huadong pharmaceutical, Borui pharmaceutical and other enterprises have been approved anda for the first time, opening a new stage of internationalization. In 2019, Chinese pharmaceutical companies were approved to apply for NDA by two US FDA new drugs, namely, Btk from Baiji and L-Amlodipine, a stone drug.

In terms of obtaining EU GMP certification and drug marketing license, from the data published by eudragmdp database, as of December 10, 2019, the total number of EU GMP certification of Chinese pharmaceutical enterprises was 453, and the number of domestic pharmaceutical enterprises passing EU GMP certification reached 47 in 2019. According to the data published on the EDQM website, as of December 10, 2019, 247 CEP certificates have been obtained by domestic pharmaceutical enterprises. (data source: China Chamber of Commerce for the import and export of medical and health products) in 2019, the export of Western medicine products reached US $41.109 billion, an increase of 11.46%. Asia, Europe and North America are the top three export markets; India, the United States and Japan are the top three export countries, of which exports to India increased by 25.88%, and exports to the United States and Japan increased by 1.98% and 7.27% respectively.

In terms of specific products, API exports reached US $33.683 billion, an increase of 12.1%, accounting for 45.62% of China's total exports of medical and health products. Anti infective drugs, hormone drugs, cardiovascular system drugs, respiratory system drugs, antipyretic and analgesic drugs, Lincomycin drugs have achieved significant growth; vitamins, aminoglycosides, penicillins, central nervous system drugs, Digestive System Drugs, Chloramphenicol, etc. have declined in different ranges; the export of new raw materials for anti-cancer drugs is 97 million US dollars. India is still China's largest exporter of APIs, with an export of US $5.653 billion, accounting for 16.78% and an increase of 25.53%, indicating that China's API industry occupies a stable position in the upper reaches of India's pharmaceutical industry. Only the second largest U.S. export in the top ten markets of API export showed a negative growth of 1.23%. The export of preparations reached 4.109 billion US dollars, a slight increase of 0.23%. The EU, Africa and the United States were the top three export markets, with the export to the EU down 16.43%, while Australia, the second largest exporter, fell 22.23%. In 2019, the performance of local pharmaceutical export enterprises was different, and the export of pharmaceutical products of Ruiyang pharmaceutical, Sinopharm, Shandong new era, Zhuhai federal, Nantong Lianya and other enterprises increased significantly. The export of newly coded anticancer drugs reached 156 million US dollars. The export of biochemical drugs reached US $3.316 billion, an increase of 21.25%.

Although the price of enzymes and coenzymes decreased by 28.65%, the substantial increase in the quantity led to an increase of 81.27% in the export volume. (data source: China Chamber of Commerce for import and export of medical and health products / health.com/china customs data)